Objective To observe the effects of concurrent radiochemotherapy on peripheral blood T lymphocyte subsets in patients with glioma， so as to provide immunological indicators for the treatment of glioma. Methods A total of 150 patients with glioma admitted to the glioma department of Beijing Shijitan Hospital from January 2015 to December 2017 were recruited into the glioma group， and the other 150 healthy people who undertook health examination in the health examination center were assigned into the control group. The content of T lymphocyte subsets in peripheral blood of healthy control group and glioma patients before and after concurrent chemoradiotherapy were determined by fluorescence- activated cell sorter（ FACS）. Results The results showed that there was no statistical significance in the difference of CD3+ in peripheral blood of patients between the two groups before treatment（ P＞0.05）. with glioma was not statistically significant （P ＞ 0.05）. The mean CD4+ and CD4+/CD8+ were significantly lower than those in healthy controls. The mean CD8+ was significantly higher than the healthy control group. The difference was statistically significant（ P ＜ 0.05）. The mean CD3+， mean CD4+ and CD4+/CD8+ of glioma patients before concurrent chemoradiotherapy were significantly higher than those after concurrent chemoradiotherapy， and the difference was statistically significant（ P＜0.05）. The mean value of CD8+ was significantly increased after treatment， and the difference was statistically significant（ P＜0.05）. Conclusions The immune function of patients with glioma is decreased. The defection in immune function after concurrent chemoradiotherapy is more obvious. Peripheral blood T lymphocyte subsets can be used as an immunological reference index for clinical evaluation of glioma concurrent chemoradiotherapy.